INT64653
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
This recombinant protein binds CD2 on T cells and Fc gamma RIII on accessory cells (e.g., natural killer cells, macrophages), inhibiting T cell activation/proliferation and inducing selective T cell apoptosis. | |||||||||||||||
| |||||||||||||||
|
The immediate and marked suppression of ongoing EAN by the mAb lead to the recommendation of anti-CD2 mAbs as candidates for T cell directed immunotherapy of the GBS. | |||||||||||||||
| |||||||||||||||
|
The peptides are produced after stimulation with the mitogenic monoclonal antibodies anti-CD2.1/2.2 and anti-CD28. | |||||||||||||||
| |||||||||||||||
|
By binding to the CD2 antigen on T cells, alefacept prevents T-cell activation and triggers apoptosis, preferentially targeting memory-effector T cells [3]. | |||||||||||||||
| |||||||||||||||
|
This study supports the notion that T cell activation plays an important role in chronic inflammatory diseases and effective blockade of the LFA-3/CD2 interaction may be useful for treating PsA. | |||||||||||||||
| |||||||||||||||
|
The CD2+, CD4+ and CD8+ levels, which are closely associated with activity of T cells, were statistically unchanged except on day 8 after acupuncture (P < 0.05). | |||||||||||||||
| |||||||||||||||
|
Cell counts of CD2+, CD4+, CD8+, CD11b+, CD16+, CD19+ and CD56+ were evaluated for variations in T cells, B cells, macrophages and NK cells after acupuncture treatment. | |||||||||||||||
| |||||||||||||||
|
Blockade of the LFA-3/CD2 interaction, a key co-stimulatory pathway, can inhibit T-cell activation. | |||||||||||||||
| |||||||||||||||
|
With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells. | |||||||||||||||
| |||||||||||||||
|
Alefacept binds competitively to the CD2 on the surface of T cells with the LFA-3 portion of the drug and efficiently interferes with LFA-3/CD2 binding and thereby T cell activation (Miller et al 1993), whereas the Fc portion of alefacept engages the immunoglobulin receptor Fc? | |||||||||||||||
| |||||||||||||||
|
Alefacept binds competitively to the CD2 on the surface of T cells with the LFA-3 portion of the drug and efficiently interferes with LFA-3/CD2 binding and thereby T cell activation (Miller et al 1993), whereas the Fc portion of alefacept engages the immunoglobulin receptor Fc? | |||||||||||||||
| |||||||||||||||
|
Alefacept is a recombinant protein that binds to CD2 on memory-effector T lymphocytes, inhibiting their activation and reducing the number of these cells. | |||||||||||||||
| |||||||||||||||
|
It competitively binds to CD2 cells on T cells to block its activation. | |||||||||||||||
| |||||||||||||||
|
Interaction of CD2 with its ligand, CD58 has been blocked by application of a soluble fully human recombinant fusion protein comprising the first extracellular domain of CD58 and the hinge, CH2 and CH3 sequences of human IgG1 (LFA-3-IgG1; alefacept). | |||||||||||||||
| |||||||||||||||
|
Cell counts of CD2+, CD4+, CD8+, CD11b+, CD16+, CD19+ and CD56+ were evaluated for variations in T cells, B cells, macrophages and NK cells after acupuncture treatment. | |||||||||||||||
| |||||||||||||||
|
Cell counts of CD2+, CD4+, CD8+, CD11b+, CD16+, CD19+ and CD56+ were evaluated for variations in T cells, B cells, macrophages and NK cells after acupuncture treatment. | |||||||||||||||
| |||||||||||||||
|
Cell counts of CD2+, CD4+, CD8+, CD11b+, CD16+, CD19+ and CD56+ were evaluated for variations in T cells, B cells, macrophages and NK cells after acupuncture treatment. | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.